A randomized controlled comparison of difference HR after the reversal of non-depolarized muscle relaxant with atropine 0.6 mg, 0.9 mg and 1.2 mg plus neostigmine 2.5 mg

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20161108003

Enrollment

Unknown

Registered

2016-11-08

Start date

2015-06-10

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

2 patients had delayed bradycardia atropine&#44

Interventions

Atropine 1.2 mg before neostigmine for reversal non&#45

depolarizng muscle relaxant ,Atropine 0.9 mg before neostigmine for reversal non&#45

depolarizng muscle relaxant ,Atropine 0.6 mg before neostigmine for reversal non&#45

depolarizing muscle relaxant

Experimental Drug,Experimental Drug,Experimental Drug

Atropine 1.2 mg ,Atropine 0.9 mg ,Atropine 0.6 mg

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Elective case for surgery undergo to general anesthesia and receive non - depolarizing muscle relaxant 2. ASA I-II 3. Age 18-65 year-old

Exclusion criteria

Exclusion criteria: 1. underlying disease: Hypertension, hyperthyroidism, arrhythmia 2. Pregnancy 3. BMI>30

Design outcomes

Primary

Measure	Time frame
difference heart rate every 1 min for 15 min then 5 min for 90 min heart rate	—

Secondary

Measure	Time frame
difference blood pressure every 1 min for 15 min then 5 min for 90 min blood pressure	—

Countries

Thailand

Contacts

Public ContactRatchayakorn Limapichat

Khonkaen hospital

kae_racha@hotmail.com0815996759

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

A randomized controlled comparison of difference HR after the reversal of non&#45;depolarized muscle relaxant with atropine 0.6 mg&#44; 0.9 mg and 1.2 mg plus neostigmine 2.5 mg